Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ORG 2766 is a synthetic analog of adrenocorticotropic hormone (ACTH) consisting of amino acids 4-9 of the ACTH sequence[1][2][3][4][6]. It acts as a **Melanocortin receptor 2 agonist (ACTH receptor agonist)** and exhibits neurotrophic effects, influencing memory, attention, and behavioral processes[1][6]. Developed primarily for neuropsychiatric and neurodegenerative disorders, it showed potential to reduce social withdrawal and stereotypic behaviors in children with autism, but clinical evidence was mixed[2][3][4]. Primary indications explored were **dementia, diabetic neuropathies, amnesia,** and **autistic disorder**[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ORG 2766.